News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Covance Inc. Reports First Quarter Revenue of $482M and EPS of $0.60; Updates Full Year Financial Targets
April 29, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PRINCETON, N.J., April 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE:CVD - News) today reported earnings for its first quarter ended March 31, 2010 of $0.60 per diluted share versus $0.63 per diluted share in the first quarter of 2009.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Drug Development
If Data Is the New Oil, AI Is the Refinery
September 8, 2025
·
5 min read
·
Lori Ellis
Neuroscience
Servier Bets $450M On Kaerus’ Fragile X Syndrome Therapy
September 8, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
AC Immune To Cut 30% of Workforce
September 5, 2025
·
196 min read
·
BioSpace Editorial Staff
China
Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
September 5, 2025
·
2 min read
·
Tristan Manalac